ArticleFrontiers in oncology2026
Clinicopathology of adenocarcinoma originating from the anal gland with immunohistochemical expressions of GATA3 and TTF-1: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenocarcinoma originating from the anal gland with immunohistochemical expression of GATA3 and TTF-1 (ACAGGT) is a rare entity. This report describes an 80-year-old female patient who detected a perianal mass without an obvious cause 10 years prior and presented to our hospital (Hangzhou, China) with local pain lasting 3 days. Preoperative B-ultrasound revealed a heterogeneous hypoechoic area in the right perianal region, adjacent to the subcutaneous tissue. Pelvic magnetic resonance imaging (MRI) with contrast enhancement showed an abscess on the right side of the anal canal. Under general anesthesia, the patient underwent lesion resection and anal sphincteroplasty. Pathological examination demonstrated that the tumor exhibited glandular and solid components with invasive growth. The stromal tumor-infiltrating lymphocyte (TIL) score was moderate (30%). Immunohistochemical staining suggested the following results: CK7 (+), GATA3 (90%, +), TTF-1 (10%, +), Vimentin (-), CK20 (-), and CDX-2 (-). The programmed death ligand 1 (PD-L1) combined positive score (CPS) was 5. Additionally, molecular testing failed to detect common driver gene mutations (e.g., KRAS/NRAS/BRAF), and the tumor was microsatellite-stable (MSS). The patient received postoperative radiotherapy. At 6 months of follow-up, metastasis to the right inguinal lymph nodes was identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.